Develops novel diagnostic tools and therapeutic strategies to combat cancer metastasis
Konstantinos Konstantopoulos is Professor of Chemical and Biomolecular Engineering, at Johns Hopkins University.
Dr. Konstantopoulos joined the faculty of Chemical & Biomolecular Engineering at the Johns Hopkins University in 1997, and promoted to the rank of Professor in 2008. He served as Department Chair of Chemical & Biomolecular Engineering from 2008 to 2017. He received his Ph.D. from Rice University in 1995, and his Dip. Eng. from the National University of Athens in 1989.
He is a project leader with the NCI-funded Johns Hopkins Physical Sciences-Oncology Center (2009-present). He was elected Fellow of the American Institute for Medical and Biological Engineering in 2009 and of the Biomedical Engineering Society in 2012. He serves on the Editorial Board of The American Journal of Physiology Cell Physiology (2005-present), Technology (2013-present) and Annual Review of Biomedical Engineering (2013-present), and as a section Editor of Current Opinion in Chemical Engineering, and as Associate Editor of the Annals of Biomedical Engineering (2009-present).
He also served as Chair of the Bioengineering Technology and Surgical Sciences (BTSS) study section of the National Institutes of Health (2011-2013). His research is at the interface of engineering and biology pertinent to cancer metastasis. He has published over 110 peer-reviewed articles in premier journals such as Cell, Proc. Natl. Acad. Sci. USA, Nature Reviews Cancer, Journal of Cell Biology, Current Biology, Blood, Current Opinion in Cell Biology etc.
Dr. Konstantopoulos has received the Robert B. Pond, Sr. Excellence in Teaching Award (2003 and 2011) and the Bioengineering Distinguished Alumnus Award from Rice University (2013). Eight of his mentees have launched successful academic careers in premier institutions such as Georgia Institute of Technology, University of Maryland College Park and Indian Institute of Technology at Bombay, whereas another ten have joined the industry setting now holding leading appointments (Director at Merck Labs, Associate Director at Alexion Pharmaceuticals etc).